Prospect on medical treatment of pulmonary mucinous adenocarcinoma
10.3760/cma.j.cn101721-20230426-000153
- VernacularTitle:晚期肺黏液腺癌的治疗进展
- Author:
Danyu LIU
1
;
Yuhong GONG
;
Xiang ZHAO
;
Meng ZHANG
;
Qi ZHANG
;
Cuiyan GUO
;
Ligong NIE
;
Yuan CHENG
Author Information
1. 北京大学第一医院呼吸和危重症医学科，北京 100034
- Keywords:
pulmonary mucinous adenocarcinoma;
invasive mucinous adenocarcinoma;
targeted therapy;
immunotherapy
- From:
Clinical Medicine of China
2023;39(4):241-245
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary mucinous adenocarcinoma is a subtype of lung adenocarcinoma, among which invasive mucinous adenocarcinoma (IMA) is the most common subtype and is easily misdiagnosed as pneumonia. Its etiology and pathogenesis are unclear and may be related to gene mutations and other factors. Due to its relative rarity and few related studies, guidelines do not provide advices on its treatment. KRAS mutations are common in IMA patients, and Sotorasib may be effective against KRAS G12C mutated IMA. NRG1 fusion is considered to be an important driver of IMA, and afatinib may be effective in treating IMA with NRG1 fusion/rearrangement. PD-L1 expression is very low in IMA patients, while B7-H3 expression is high, so B7-H3 may be a potential immunotherapeutic target.
